Table 3 General characteristics of the studies included in the review

Macedo et al. (2012) [7]

To collect current data and evaluate the effect of bevacizumab on first-line therapy, focusing on each backbone regimen; subgroup analysis.

Systematic review

PFS and OS

Hurwitz et al. (2013) [17]

To describe the results of the analysis of RCTs on bevacizumab in mCRC. The analysis pooled individual patient data from these studies, which allowed a more comprehensive examination of efficacy and safety of bevacizumab.

Systematic review

PFS and OS

Saltz et al. (2008) [4]

To evaluate the efficacy and safety of bevacizumab when added to oxaliplatin in first-line therapy (capecitabin plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX]) in mCRC patients.

RCT

PFS and OS

Tournigand et al. (2004) [12]

To evaluate FOLFIRI and FOLFOX regimens to determine the best sequence (FOLFIRI or FOLFOX first) to treat mCRC patients.

RCT

PFS and OS

Van Cutsem et al. (2007) [18]

To compare panitumumab plus supportive care versus supportive care in mCRC patients who had progressed after standard chemotherapy.

RCT

PFS and OS